Improvement in stroke mortality in Canada and the United States, 1990 to 2002

Circulation

Volumn 113, Issue 10, 2006, Pages 1335-1343

  Yang, Quanhe ^a   Botto, Lorenzo D ^b   Erickson, J David ^a   Berry, Robert J ^a   Sambell, Christie ^c   Johansen, Helen ^c   Friedman, J M ^d  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c HEALTH STATISTICS DIVISION   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Mortality; Nutrition; Population; Prevention; Stroke

Indexed keywords

FOLIC ACID; HOMOCYSTEINE;

ARTICLE; CANADA; CONCENTRATION RESPONSE; EPIDEMIOLOGICAL DATA; FEMALE; HOMOCYSTEINE BLOOD LEVEL; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; STROKE; UNITED KINGDOM; UNITED STATES; VITAMIN SUPPLEMENTATION; ADULT; AGE DISTRIBUTION; AGED; BLOOD; CEREAL; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; DIET SUPPLEMENTATION; MIDDLE AGED; RACE; SEX DIFFERENCE; STATISTICAL MODEL;

ADULT; AGE DISTRIBUTION; AGED; CANADA; CEREALS; CEREBROVASCULAR ACCIDENT; CONTINENTAL POPULATION GROUPS; ENGLAND; FOLIC ACID; FOOD, FORTIFIED; HOMOCYSTEINE; HUMANS; LINEAR MODELS; MIDDLE AGED; RISK FACTORS; SEX FACTORS; UNITED STATES; WALES;

EID: 33645743547     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.570846     Document Type: Article

References (56)

1. Food and Drug Administration. Food additives permitted for direct addition to food for human consumption: folic acid (folacin), final rule. Fed Reg. 1996;8797-8807.
2. Centers for Disease Control and Prevention. Folate status in women of childbearing age, by race/ethnicity: United States, 1999-2000. MMWR Morb Mortal Wkly Rep. 2002;51:808-810.
3. Honein MA, Paulozzi LJ, Mathews TJ, Erickson JD, Wong LY. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA. 2001;285:2981-2986.
4. Williams LJ, Rasmussen SA, Flores A, Kirby RS, Edmonds LD. Decline in the prevalence of spina bifida and anencephaly by race/ethnicity: 1995-2002. Pediatrics. 2005;116:580-586.
5. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999;340:1449-1454.
6. Health Canada. Regulations amending the food and drug regulations: schedule No. 1066 (flour fortification). Canada Gazette Part II. Volume 132, issue 24, 1998.
7. Ray JG, Vermeulen MJ, Boss SC, Cole DE. Increased red cell folate concentrations in women of reproductive age after Canadian folic acid food fortification. Epidemiology. 2002;13:238-240.
8. Miriuka SG, Langman LJ, Keren ES, Miner SE, Mamer OA, Delgado DH, Evrovski J, Ross HJ, Cole DE. Effects of folic acid fortification and multivitamin therapy on homocysteine and vitamin B(12) status in cardiac transplant recipients. J Heart Lung Transplant. 2004;23:405-412.
9. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015-2022.
10. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325:1202.
11. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet. 2005;365:224-232.
12. Cronin S, Furie KL, Kelly PJ. Dose-related association of MTHFR 677T allele with risk of ischemic stroke: evidence from a cumulative meta-analysis. Stroke. 2005;36:1581-1587.
13. Centers for Disease Control and Prevention. Decline in deaths from heart disease and stroke-United States, 1900-1999. JAMA. 1999;282:724-726.
14. Heart and Stroke Foundation of Canada. The Growing Burden of Heart Disease and Stroke in Canada 2003. Ottawa, Canada: Heart and Stroke Foundation of Canada; 2003.
15. Cooper R, Cutler J, Desvigne-Nickens P, Fortmann SP, Friedman L, Havlik R, Hogelin G, Marler J, McGovern P, Morosco G, Mosca L, Pearson T, Stamler J, Stryer D, Thom T. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the National Conference on Cardiovascular Disease Prevention. Circulation. 2000;102:3137-3147.
16. Gillum RF. New considerations in analyzing stroke and heart disease mortality trends: the Year 2000 Age Standard and the International Statistical Classification of Diseases and Related Health Problems, 10th Revision. Stroke. 2002;33:1717-1721.
17. Geran L, Tully P, Wood P. A comparability study for the implementation of the Tenth Revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) for mortality data in Canada: preliminary results. Ottawa, Canada: Statistics Canada; 2004. Health Statistics Division internal working document,
18. Griffiths C, Brock A, Rooney C. The impact of introducing ICD-10 on trends in mortality from circulatory diseases in England and Wales. Health Stat Q. 2004:14-20.
19. Anderson RN, Minino AM, Hoyert DL, Rosenberg HM. Comparability of cause of death between ICD-9 and ICD-10: preliminary estimates. Natl Vital Stat Rep. 2001;49:1-32.
20. Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia, Pa: Lippincott-Raven; 1998.
21. Raiten DJ, Fisher KD. Assessment of folate methodology used in the Third National Health and Nutrition Examination Survey (NHANES III, 1988-1994). J Nutr. 1995;125:1371S-1398S.
22. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1987;422:43-52.
23. Pfeiffer CM, Huff DL, Gunter EW. Rapid and accurate HPLC assay for plasma total homocysteine and cysteine in a clinical laboratory setting. Clin Chem. 1999;45:290-292.
24. Canto JG, Iskandrian AE. Major risk factors for cardiovascular disease: debunking the "only 50%" myth. JAMA. 2003;290:947-949.
25. Davis PH, Dambrosia JM, Schoenberg BS, Schoenberg DG, Pritchard DA, Lilienfeld AM, Whisnant JP. Risk factors for ischemic stroke: a prospective study in Rochester, Minnesota. Ann Neurol. 1987;22:319-327.
26. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication. the Framingham Study. Stroke. 1994;25:40-43.
27. Gorelick PB, Sacco RL, Smith DB, Alberts M, Mustone-Alexander L, Rader D, Ross JL, Raps E, Ozer MN, Brass LM, Malone ME, Goldberg S, Booss J, Hanley DF, Toole JF, Greengold NL, Rhew DC. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA. 1999;281:1112-1120.
28. Pocock SJ, McCormack V, Gueyffier F, Boutitie F, Fagard RH, Boissel JP. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ. 2001;323:75-81.
29. Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: scientific review. JAMA. 2002;288:1388-1395.
30. Mills JL, Signore C. Neural tube defect rates before and after food fortification with folic acid. Birth Defects Res A Clin Mol Teratol. 2004;70:844-845.
31. Busby A, Armstrong B, Dolk H, Armstrong N, Haeusler M, Berghold A, Gillerot Y, Baguette A, Gjergja R, Barisic I, Christiansen M, Goujard J, Steinbicker V, Rosch C, McDonnell R, Scarano G, Calzolari E, Neville A, Cocchi G, Bianca S, Gatt M, Walle HD, Braz P, Latos-Bielenska A, Gener B, Portillo I, Addor MC, Abramsky L, Ritvanen A, Robert-Gnansia E, Daltveit AK, Aneren G, Olars B, Edwards G. Preventing neural tube defects in Europe: a missed opportunity. Reprod Toxicol. 2005;20:393-402.
32. Botto LD, Lisi A, Robert-Gnansia E, Erickson JD, Vollset SE, Mastroiacovo P, Botting B, Cocchi G, de Vigan C, de Walle H, Feijoo M, Irgens LM, McDonnell B, Merlob P, Ritvanen A, Scarano G, Siffel C, Metneki J, Stoll C, Smithells R, Goujard J. International retrospective cohort study of neural tube defects in relation to folic acid recommendations: are the recommendations working? BMJ. 2005;330:571.
33. Fang J, Alderman MH. Trend of stroke hospitalization, United States, 1988-1997. Stroke. 2001;32:2221-2226.
34. Field TS, Green TL, Roy K, Pedersen J, Hill MD. Trends in hospital admission for stroke in Calgary. Can J Neurol Sci. 2004;31:387-393.
35. Muntner P, Garrett E, Klag MJ, Coresh J. Trends in stroke prevalence between 1973 and 1991 in the US population 25 to 74 years of age. Stroke. 2002;33:1209-1213.
36. Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol. 2003;2:43-53.
37. Unger C, Weiser JK, McCullough RE, Keefer S, Moore LG. Altitude, low birth weight, and infant mortality in Colorado. JAMA. 1988;259:3427-3432.
38. Paneth N, Kiely JL, Wallenstein S, Marcus M, Pakter J, Susser M. Newborn intensive care and neonatal mortality in low-birth-weight infants: a population study. N Engl J Med. 1982;307:149-155.
39. Mark SD, Wang W, Fraumeni JF Jr, Li JY, Taylor PR, Wang GQ, Guo W, Dawsey SM, Li B, Blot WJ. Lowered risks of hypertension and cerebrovascular disease after vitamin/mineral supplementation: the Linxian Nutrition Intervention Trial. Am J Epidemiol. 1996;143:658-664.
40. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565-575.
41. Spence JD, Bang H, Chambless LE, Stampfer MJ. Vitamin Intervention for Stroke Prevention Trial: an efficacy analysis. Stroke. 2005;36:2404-2409.
42. Young TK, Hachinski V. The population approach to stroke prevention: a Canadian perspective. Clin Invest Med. 2003;26:78-86.
43. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199-206.
44. Greenlund KJ, Zheng ZJ, Keenan NL, Giles WH, Casper ML, Mensah GA, Croft JB. Trends in self-reported multiple cardiovascular disease risk factors among adults in the United States, 1991-1999. Arch Intern Med. 2004;164:181-188.
45. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195-1200.
46. Siegel D, Lopez J, Meier J. Use of cholesterol-lowering medications in the United States from 1991 to 1997. Am J Med. 2000;108:496-499.
47. Ford ES, Mokdad AH, Giles WH, Mensah GA. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation. 2003;107:2185-2189.
48. Gilmore J Report on Smoking in Canada, 1985 to 2001. Statistics Canada. 2002. Catalog 82F007Xie.
49. Tremblay MS, Katzmarzyk PT, Willms JD. Temporal trends in overweight and obesity in Canada, 1981-1996. Int J Obes Relat Metab Disord. 2002;26:538-543.
50. Tanuseputro P, Manuel DG, Leung M, Nguyen K, Johansen H. Risk factors for cardiovascular disease in Canada. Can J Cardiol. 2003;19:1249-1259.
51. Gregg EW, Cheng YJ, Cadwell BL, Imperatore G, Williams DE, Flegal KM, Narayan KM, Williamson DF. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA. 2005;293:1868-1874.
52. Grundy SM, D'Agostino RB Sr, Mosca L, Burke GL, Wilson PW, Rader DJ, Cleeman JI, Roccella EJ, Cutler JA, Friedman LM. Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood Institute workshop. Circulation. 2001;104:491-496.
53. Hunink MG, Goldman L, Tosteson AN, Mittleman MA, Goldman PA, Williams LW, Tsevat J, Weinstein MC. The recent decline in mortality from coronary heart disease, 1980-1990: the effect of secular trends in risk factors and treatment. JAMA. 1997;277:535-542.
54. Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM, Gutnikov SA, Edwards P, Mant D, Sackley CM, Farmer A, Sandercock PA, Dennis MS, Warlow CP, Bamford JM, Anslow P. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet. 2004;363:1925-1933.
55. Campbell NR, Tu K, Brant R, Duong-Hua M, McAlister FA. The impact of the Canadian Hypertension Education Program on antihypertensive prescribing trends. Hypertension. 2006;47:22-28.
56. Sorlie PD, Backlund E, Keller JB. US mortality by economic, demographic, and social characteristics: the National Longitudinal Mortality Study. Am J Public Health. 1995;85:949-956.